These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
375 related articles for article (PubMed ID: 28623843)
21. Herpes Zoster Rates in a Large Cohort of Patients With Systemically Treated Psoriasis. Levandoski KA; Quesenberry CP; Tsai AL; Asgari MM JAMA Dermatol; 2018 Feb; 154(2):218-219. PubMed ID: 29261840 [TBL] [Abstract][Full Text] [Related]
22. Switching biologics in severe pediatric psoriasis: a retrospective analysis. Ramos Pinheiro R; Diamantino F; Cabete J; Brasileiro A; Baptista J; Lopes MJP Int J Dermatol; 2017 Dec; 56(12):1461-1464. PubMed ID: 28960270 [No Abstract] [Full Text] [Related]
23. Prevalence of Phototherapy in the Age of Biologics. Calzavara-Pinton P; Zanca A; Arisi M; Rossi MT; Zane C; Venturini M; Ortel B Dermatology; 2018; 234(5-6):166-172. PubMed ID: 30205372 [TBL] [Abstract][Full Text] [Related]
24. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. Reich K; Burden AD; Eaton JN; Hawkins NS Br J Dermatol; 2012 Jan; 166(1):179-88. PubMed ID: 21910698 [TBL] [Abstract][Full Text] [Related]
25. Why Biologic Therapies Sometimes Lose Efficacy. Strober BE Semin Cutan Med Surg; 2016 Jun; 35(4 Suppl 4):S78-80. PubMed ID: 27525443 [TBL] [Abstract][Full Text] [Related]
26. Use of biologic agents in pediatric psoriasis. Marji JS; Marcus R; Moennich J; Mackay-Wiggan J J Drugs Dermatol; 2010 Aug; 9(8):975-86. PubMed ID: 20684148 [TBL] [Abstract][Full Text] [Related]
27. The treatment of moderate-to-severe psoriasis: prescreening and monitoring psoriatic patients on biologics. Levine D; Strober BE Semin Cutan Med Surg; 2010 Mar; 29(1):28-34. PubMed ID: 20430305 [TBL] [Abstract][Full Text] [Related]
28. Reduced doses of biological therapies in psoriasis: a new potentially "sustainable" frontier of psoriasis treatment. Ribero S; Ortoncelli M; Mastorino L; Quaglino P; Dapavo P Expert Opin Biol Ther; 2023; 23(9):867-868. PubMed ID: 37553946 [No Abstract] [Full Text] [Related]
29. Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective. Ross C; Marshman G; Grillo M; Stanford T Australas J Dermatol; 2016 May; 57(2):137-40. PubMed ID: 25754697 [TBL] [Abstract][Full Text] [Related]
30. Comparison of Management Guidelines for Moderate-to-Severe Plaque Psoriasis: A Review of Phototherapy, Systemic Therapies, and Biologic Agents. Ighani A; Partridge ACR; Shear NH; Lynde C; Gulliver WP; Sibbald C; Fleming P J Cutan Med Surg; 2019; 23(2):204-221. PubMed ID: 30463416 [TBL] [Abstract][Full Text] [Related]
31. The role of biologics in the treatment of moderate-to-severe plaque psoriasis. Puig L G Ital Dermatol Venereol; 2017 Feb; 152(1):28-35. PubMed ID: 27627100 [TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study. Viguier M; Pagès C; Aubin F; Delaporte E; Descamps V; Lok C; Beylot-Barry M; Séneschal J; Dubertret L; Morand JJ; Dréno B; Bachelez H; Br J Dermatol; 2012 Aug; 167(2):417-23. PubMed ID: 22413927 [TBL] [Abstract][Full Text] [Related]
33. Biologics for psoriasis: more drugs, new patient categories, but fresh challenges for clinical dermatologists. Pink AE; Smith CH Br J Dermatol; 2017 Jul; 177(1):7-8. PubMed ID: 28731243 [No Abstract] [Full Text] [Related]
34. Sustained Psoriasis Area and Severity Index, Dermatology Life Quality Index and EuroQol-5D response of biological treatment in psoriasis: 10 years of real-world data in the Swedish National Psoriasis Register. Hjalte F; Carlsson KS; Schmitt-Egenolf M Br J Dermatol; 2018 Jan; 178(1):245-252. PubMed ID: 28644904 [TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany. Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105 [TBL] [Abstract][Full Text] [Related]
36. Current therapeutic approaches of psoriasis are affected by age at disease onset. Di Lernia V; Ficarelli E J Dermatolog Treat; 2014 Feb; 25(1):15-7. PubMed ID: 23210896 [TBL] [Abstract][Full Text] [Related]
37. Combining biologics with methotrexate in psoriasis: a systematic review. van Bezooijen JS; Prens EP; Pradeepti MS; Atiqi R; Schreurs MWJ; Koch BCP; van Gelder T; van Doorn MBA Br J Dermatol; 2015 Jun; 172(6):1676-1680. PubMed ID: 25470815 [No Abstract] [Full Text] [Related]
38. Differential blood cellular profile in patients with moderate-to-severe psoriasis treated with classical systemic therapies: a step forward in personalized medicine. Hernández-Breijo B; Jurado T; Rodríguez-Martín E; Martínez-Feito A; Plasencia-Rodríguez C; Balsa A; Alonso-Pacheco ML; Villar LM; Herranz-Pinto P; Pascual-Salcedo D Br J Dermatol; 2018 Sep; 179(3):765-766. PubMed ID: 29526036 [No Abstract] [Full Text] [Related]
39. Current pharmacological treatment guidelines for psoriasis and psoriatic arthritis. Stiff KM; Glines KR; Porter CL; Cline A; Feldman SR Expert Rev Clin Pharmacol; 2018 Dec; 11(12):1209-1218. PubMed ID: 30449211 [TBL] [Abstract][Full Text] [Related]
40. Durable dermatology life quality index improvements in patients on biologics associated with psoriasis areas and severity index: a longitudinal study. Chaptini C; Quinn S; Marshman G Australas J Dermatol; 2016 Aug; 57(3):e72-5. PubMed ID: 26010650 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]